These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 21406406)

  • 1. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter.
    Dumont AG; Reynoso DG; Trent JC
    Cancer Res; 2011 Mar; 71(6):2403; author reply 2404. PubMed ID: 21406406
    [No Abstract]   [Full Text] [Related]  

  • 2. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
    Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
    Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
    Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
    Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
    Tang M; Li DQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transforming effect of PDGFRA gene mutant on the cell function in gastrointestinal stromal tumor].
    Yang L; Bai CG; Hou XW; Liu XH; Ma DL
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):500-4. PubMed ID: 19950696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].
    Wang CM; Shi YQ; Fu H; Zhao GF; Zhou Y; Du CY; Ye YW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May; 13(5):371-4. PubMed ID: 20499309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y.
    Thalheimer A; Schlemmer M; Bueter M; Merkelbach-Bruse S; Schildhaus HU; Buettner R; Hartung E; Thiede A; Meyer D; Fein M; Maroske J; Wardelmann E
    Am J Surg Pathol; 2008 Oct; 32(10):1560-5. PubMed ID: 18724244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
    Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
    [No Abstract]   [Full Text] [Related]  

  • 19. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
    Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
    Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological and molecular features of the gastrointestinal stromal tumor].
    Sugai T; Uesugi N; Yamada N; Takahashi K; Wakabayashi G; Terashima M; Chiba T; Suzuki K
    Gan To Kagaku Ryoho; 2011 May; 38(5):715-21. PubMed ID: 21566429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.